TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive In Brief: NIH Reviewers, Advisors To Get Increase In Honoraria; Price Leaving NCI for Maryland March 14, 1980